91158-10-0

Upstream product

• 21204-67-1 methyl (triphenylphosphoranylidene)acetate 
• 637-88-7 1,4-Cyclohexanedione 
• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 1407169-65-6 4-(bromomethylidene)cyclohexanone 

Downstream Products

• 66405-41-2 (4-oxo-cyclohexyl)-acetic acid methyl ester 
• 886587-62-8 {4-[bis-(4-hydroxy-phenyl)-methylene]-cyclohexyl}-acetic acid methyl ester 
• 886587-96-8 4-ethyl[bis(4-methoxymethoxyphenyl)methylene]cyclohexane 
• 886587-66-2 4-(2-hydroxyethyl)[bis(4-methoxymethoxyphenyl)methylene]cyclohexane 
• 900790-35-4 4-(2-fluoroethyl)[bis(4-methoxymethoxyphenyl)methylene]cyclohexane 
• 886587-64-0 methyl {4-[bis(4-methoxymethoxyphenyl)methylene]cyclohexyl}acetate 
• 886587-72-0 4-(2-methanesulfonylethyl)[bis(4-methoxymethoxyphenyl)methylene]cyclohexane 
• 886587-95-7 4-[2-(4-fluorobutoxy)ethyl][bis(4-methoxymethoxyphenyl)methylene]cyclohexane 
• 110852-22-7 (4-hydroxy-cyclohexylidene)-acetic acid methyl ester 
• 7171-78-0 <4-Methyl-cyclohexen-(3)-yl>-essigsaeure-methylester 

Relevant academic research and scientific papers

PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS

Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa)

Induced axial chirality in biocatalytic asymmetric ketone reduction

Catalytic asymmetric reduction of prochiral ketones of type 4-alkylidene cyclohexanone with formation of the corresponding axially chiral R-configurated alcohols (up to 99% ee) was achieved using alcohol dehydrogenases, whereas chiral transition-metal catalysts fail. Reversal of enantioselectivity proved to be possible by directed evolution based on saturation mutagenesis (up to 98% ee (S)). Utilization of ketone with a vinyl bromide moiety allows respective R- and S-alcohols to be exploited as key compounds in Pd-catalyzed cascade reactions.

NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE

The present invention relates to a compound or a pharmacologically acceptable salt thereof having an excellent DGAT inhibitory effect and feeding suppressant effect. The present invention provides a compound represented by the general formula (I), or pharmacologically acceptable salt thereof: [wherein, R1 represents a phenylaminocarbonyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group A, a benzoxazol-2-yl group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group A, or the like; R2 independently represents a C1-C6 alkyl group; R3 represents a group represented by the formula -C(=O)-O-R4 or the like; R4 represents a hydrogen atom, a C1-C6 alkyl group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group B, or the like; X represents an oxygen atom, a methylene group, or a group represented by the formula -NH-, or the like; L represents a single bond, a methylene group, or the like;...... represents a single bond or a double bond; m represents 1 or 2; n represents an integer of 0 to 5; Substituent Group A represents a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a C1-C6 alkoxy group, or the like; and Substituent Group B represents a C3-C6 cycloalkyl group, a phenyl group, a carboxyl group, or the like].

Fluorine-substituted cyclofenil derivatives as estrogen receptor ligands: Synthesis and structure-affinity relationship study of potential positron emission tomography agents for imaging estrogen receptors in breast cancer

In a search for estrogen receptor (ER) ligands to be radiolabeled with fluorine-18 for imaging of ER-positive breast tumors with positron emission tomography (PET), we investigated cyclofenil analogues substituted at the C3 or C4 position of the cyclohexyl group. McMurry coupling of 4,4′- dihydroxybenzophenone with various ketones produced key cyclofenil intermediates, from which C3 and C4 substituents containing alkyl and various oxygen or fluorine-substituted alkyl groups were elaborated. Binding assays to both ERα and ERβ revealed that the C3 site is more tolerant of steric bulk and polar groups than the C4 site, consistent with a computational model of the ERα ligand binding pocket. Fluorine substitution is tolerated very well at some sites, giving some compounds having affinities comparable to or higher than that of estradiol. These fluoro and fluoroalkyl cyclofenils merit further consideration as fluorine-18 labeled ER ligands for PET imaging of ERs in breast tumors.

RING CLEAVAGE AND RECONSTRUCTION OF FIVE AND SIX MEMBERED RING

Under the acetalization conditions using BF3-etherate/ethylene glycol, cyclopentanones and cyclohexanones with the carbonyl function at the C3- or C4-position of the β-side chain undergo the facile ring cleavage to reconstruct the new ring.